Bio-Works two largest shareholders, Staffan Persson and Erik Åfors, the chairman of the board Peter Ehrenheim, and members of the board Thomas Gür and Jonas Ahlén and the CEO, have all exercised their TO2 Warrants in accordance with intention expressed in press releases of the 18 and 19 of August. Bio-Works Technologies AB’s announced, on the 16’th of October, that a total of 17,854,180 TO 2 Warrants were exercised during the fourth exercise period.  Bio-Works thus received SEK 17,854,180 before issue costs. All four board members in Bio-Works have now exercised all their Warrants TO2.

Staffan Persson has informed Bio-Works that he has exercised all his outstanding Warrants TO2, owned directly or indirectly, through his holding in Swedia Invest AB. Staffan Persson now holds 22,278,063 shares in Bio-Works Technologies AB, representing 22,7 % of the total number of shares in Bio-Works Technologies  AB. Prior to the transaction his holding amounted to approximately 18.6 percent of the Company’s share capital and voting rights.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.